[{"AccountsPayableAndAccruedLiabilitiesCurrent_0_Q2_USD":28398000.0,"InvestmentIncomeNetAmortizationOfDiscountAndPremium_2_Q2_USD":420000.0,"OtherLiabilitiesNoncurrent_0_Q2_USD":1735000.0,"EmployeeRelatedLiabilitiesCurrent_0_Q2_USD":5536000.0,"AllocatedShareBasedCompensationExpense_2_Q2_USD":7013000.0,"AllocatedShareBasedCompensationExpense_1_Q2_USD":3069000.0,"AccumulatedOtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentNetOfTax_0_Q2_USD":10000.0,"CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_0_Q2_USD":95883000.0,"WeightedAverageNumberDilutedSharesOutstandingAdjustment_2_Q2_shares":821959.0,"WeightedAverageNumberDilutedSharesOutstandingAdjustment_1_Q2_shares":580089.0,"ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_2_Q2_USD":5.65,"InventoryFinishedGoodsNetOfReserves_0_Q2_USD":1384000.0,"EarningsPerShareDiluted_1_Q2_USD":0.16,"EarningsPerShareDiluted_2_Q2_USD":0.17,"ProceedsFromStockOptionsExercised_2_Q2_USD":4079000.0,"DeferredIncomeTaxExpenseBenefit_2_Q2_USD":2019000.0,"DeferredIncomeTaxAssetsNet_0_Q2_USD":85558000.0,"IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments_2_Q2_USD":12330000.0,"IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments_1_Q2_USD":11089000.0,"OtherComprehensiveIncomeLossNetOfTax_2_Q2_USD":347000.0,"OtherComprehensiveIncomeLossNetOfTax_1_Q2_USD":-185000.0,"ComprehensiveIncomeNetOfTax_2_Q2_USD":9547000.0,"ComprehensiveIncomeNetOfTax_1_Q2_USD":8529000.0,"AdditionalPaidInCapitalCommonStock_0_Q2_USD":642398000.0,"OtherAccruedLiabilitiesCurrent_0_Q2_USD":2518000.0,"WeightedAverageNumberOfSharesOutstandingBasic_2_Q2_shares":54153812.0,"WeightedAverageNumberOfSharesOutstandingBasic_1_Q2_shares":54501308.0,"StockIssuedDuringPeriodValueShareBasedCompensation_1_Q2_USD":3600000.0,"AccruedRoyaltiesCurrent_0_Q2_USD":5418000.0,"AccumulatedOtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax_0_Q2_USD":586000.0,"AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_1_Q2_USD":3069000.0,"AssetsFairValueDisclosure_0_Q2_USD":287062000.0,"RevenueFromContractWithCustomerExcludingAssessedTax_1_Q2_USD":62207000.0,"PurchaseObligationFutureMinimumPaymentsRemainderOfFiscalYear_0_Q2_USD":500000.0,"PurchaseObligationDueInThirdYear_0_Q2_USD":500000.0,"PurchaseObligationDueInSecondYear_0_Q2_USD":1000000.0,"ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities_2_Q2_USD":174739000.0,"PaymentsToAcquireAvailableForSaleSecuritiesDebt_2_Q2_USD":151124000.0,"OtherNoncashIncomeExpense_2_Q2_USD":-695000.0,"OtherComprehensiveIncomeLossTax_2_Q2_USD":103000.0,"OtherComprehensiveIncomeLossTax_1_Q2_USD":-57000.0,"OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentBeforeTax_2_Q2_USD":-3000.0,"OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentBeforeTax_1_Q2_USD":10000.0,"OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentBeforeTax_2_Q2_USD":453000.0,"OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentBeforeTax_1_Q2_USD":-252000.0,"EarningsPerShareBasic_1_Q2_USD":0.16,"OperatingLeaseRightOfUseAsset_0_Q2_USD":10601000.0,"OperatingLeaseLiabilityCurrent_0_Q2_USD":2181000.0,"NumberOfOperatingSegments_2_Q2_Segment":1.0,"InventoryNoncurrent_0_Q2_USD":2544000.0,"EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_2_Q2_USD":23000.0,"DebtSecuritiesAvailableForSaleRealizedGainLoss_2_Q2_USD":229000.0,"CostOfGoodsAndServiceExcludingDepreciationDepletionAndAmortization_2_Q2_USD":11054000.0,"CostOfGoodsAndServiceExcludingDepreciationDepletionAndAmortization_1_Q2_USD":5847000.0,"CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_2_Q2_USD":50233000.0,"AvailableForSaleSecuritiesDebtSecuritiesCurrent_0_Q2_USD":244544000.0,"AvailableForSaleSecuritiesDebtSecurities_0_Q2_USD":244544000.0,"AvailableForSaleDebtSecuritiesAmortizedCostBasis_0_Q2_USD":243784000.0,"AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_0_Q2_USD":10000.0,"AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_0_Q2_USD":770000.0,"OperatingLeaseLiabilityNoncurrent_0_Q2_USD":11720000.0,"EarningsPerShareBasic_2_Q2_USD":0.17,"ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice_2_Q2_USD":14.29,"ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod_2_Q2_shares":545104.0,"PrepaidExpenseAndOtherAssetsCurrent_0_Q2_USD":15041000.0,"PaymentsToAcquirePropertyPlantAndEquipment_2_Q2_USD":583000.0,"NetIncomeLoss_2_Q2_USD":9200000.0,"NetIncomeLoss_1_Q2_USD":8714000.0,"NetCashProvidedByUsedInOperatingActivities_2_Q2_USD":23099000.0,"NetCashProvidedByUsedInInvestingActivities_2_Q2_USD":23032000.0,"NetCashProvidedByUsedInFinancingActivities_2_Q2_USD":4079000.0,"LiabilitiesCurrent_0_Q2_USD":61592000.0,"LiabilitiesAndStockholdersEquity_0_Q2_USD":506631000.0,"Liabilities_0_Q2_USD":75047000.0,"InventoryNet_0_Q2_USD":1384000.0,"IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_2_Q2_USD":591000.0,"IncreaseDecreaseInAccountsReceivable_2_Q2_USD":-1672000.0,"PropertyPlantAndEquipmentNet_0_Q2_USD":3744000.0,"IncomeTaxExpenseBenefit_2_Q2_USD":3130000.0,"Depreciation_2_Q2_USD":694000.0,"CostsAndExpenses_2_Q2_USD":111161000.0,"CostsAndExpenses_1_Q2_USD":53036000.0,"CommonStockValue_0_Q2_USD":55000.0,"CommonStockSharesOutstanding_0_Q2_shares":54628336.0,"CommonStockSharesIssued_0_Q2_shares":54628336.0,"CashAndCashEquivalentsAtCarryingValue_0_Q2_USD":95305000.0,"AssetsCurrent_0_Q2_USD":380861000.0,"Assets_0_Q2_USD":506631000.0,"AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_2_Q2_shares":3454524.0,"AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_1_Q2_shares":3813824.0,"AccumulatedOtherComprehensiveIncomeLossNetOfTax_0_Q2_USD":596000.0,"AccountsReceivableNetCurrent_0_Q2_USD":24587000.0,"IncomeTaxExpenseBenefit_1_Q2_USD":2375000.0,"RevenueFromContractWithCustomerExcludingAssessedTax_2_Q2_USD":120207000.0,"RetainedEarningsAccumulatedDeficit_0_Q2_USD":-211465000.0,"Revenues_2_Q2_USD":120207000.0,"FiniteLivedIntangibleAssetsNet_0_Q2_USD":22298000.0,"AccruedProfessionalFeesCurrent_0_Q2_USD":6286000.0,"OtherIncome_2_Q2_USD":3284000.0,"OtherIncome_1_Q2_USD":1918000.0,"IncreaseDecreaseInInventories_2_Q2_USD":-10000.0,"IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_2_Q2_USD":883000.0,"AmortizationOfIntangibleAssets_2_Q2_USD":739000.0,"AmortizationOfIntangibleAssets_1_Q2_USD":369000.0,"WeightedAverageNumberOfDilutedSharesOutstanding_2_Q2_shares":54975771.0,"WeightedAverageNumberOfDilutedSharesOutstanding_1_Q2_shares":55081397.0,"ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_2_Q2_pure":0.0128,"ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_2_Q2_pure":0.0,"ShareBasedCompensation_2_Q2_USD":7013000.0,"Revenues_1_Q2_USD":62207000.0,"SellingGeneralAndAdministrativeExpense_2_Q2_USD":70938000.0,"ResearchAndDevelopmentExpense_2_Q2_USD":28430000.0,"ResearchAndDevelopmentExpense_1_Q2_USD":12903000.0,"PreferredStockValue_0_Q2_USD":0.0,"PreferredStockSharesOutstanding_0_Q2_shares":0.0,"PreferredStockSharesIssued_0_Q2_shares":0.0,"PreferredStockSharesAuthorized_0_Q2_shares":20000000.0,"PreferredStockParOrStatedValuePerShare_0_Q2_USD":0.001,"OperatingIncomeLoss_2_Q2_USD":9046000.0,"OperatingIncomeLoss_1_Q2_USD":9171000.0,"CommonStockSharesAuthorized_0_Q2_shares":150000000.0,"CommonStockParOrStatedValuePerShare_0_Q2_USD":0.001,"CommitmentsAndContingencies_0_Q2_USD":null,"StockholdersEquity_0_Q2_USD":431584000.0,"SellingGeneralAndAdministrativeExpense_1_Q2_USD":33917000.0,"ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate_2_Q2_pure":0.52,"Ticker":"VNDA","CIK":"1347178","name":"VANDA PHARMACEUTICALS INC.","OfficialName":"Vanda Pharmaceuticals Inc. Common Stock","form":"10-Q","period":"20200630","fy":"2020.0","fp":"Q2","qtrs":"0","uom":"USD","footnote":"nan","Market Cap":"633424667.0","Country":"United States","Sector":"Health Care","Industry":"Biotechnology: Pharmaceutical Preparations","Market":"NASDAQ","SP500":"nan","filed":"20200806"}]